AU2001271055A1 - Pharmaceutical composition improved in peroral absorbability - Google Patents

Pharmaceutical composition improved in peroral absorbability

Info

Publication number
AU2001271055A1
AU2001271055A1 AU2001271055A AU2001271055A AU2001271055A1 AU 2001271055 A1 AU2001271055 A1 AU 2001271055A1 AU 2001271055 A AU2001271055 A AU 2001271055A AU 2001271055 A AU2001271055 A AU 2001271055A AU 2001271055 A1 AU2001271055 A1 AU 2001271055A1
Authority
AU
Australia
Prior art keywords
pharmaceutical composition
composition improved
peroral absorbability
peroral
absorbability
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
AU2001271055A
Other versions
AU2001271055B2 (en
Inventor
Hiromu Kondo
Kiyo Nakanishi
Kazuhiro Sako
Toyohiro Sawada
Shigeo Takemura
Yuuki Tsutsui
Shunsuke Watanabe
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Astellas Pharma Inc
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Priority claimed from PCT/JP2001/006135 external-priority patent/WO2002005786A1/en
Publication of AU2001271055A1 publication Critical patent/AU2001271055A1/en
Application granted granted Critical
Publication of AU2001271055B2 publication Critical patent/AU2001271055B2/en
Assigned to ASTELLAS PHARMA INC. reassignment ASTELLAS PHARMA INC. Request for Assignment Assignors: YAMANOUCHI PHARMACEUTICAL CO., LTD.
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

AU2001271055A 2000-07-17 2001-07-16 Pharmaceutical composition improved in peroral absorbability Ceased AU2001271055B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US21898000P 2000-07-17 2000-07-17
US60218980 2000-07-17
PCT/JP2001/006135 WO2002005786A1 (en) 2000-07-17 2001-07-16 Pharmaceutical composition improved in peroral absorbability

Publications (2)

Publication Number Publication Date
AU2001271055A1 true AU2001271055A1 (en) 2002-05-02
AU2001271055B2 AU2001271055B2 (en) 2005-07-07

Family

ID=22817283

Family Applications (2)

Application Number Title Priority Date Filing Date
AU7105501A Pending AU7105501A (en) 2000-07-17 2001-07-16 Pharmaceutical composition improved in peroral absorbability
AU2001271055A Ceased AU2001271055B2 (en) 2000-07-17 2001-07-16 Pharmaceutical composition improved in peroral absorbability

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AU7105501A Pending AU7105501A (en) 2000-07-17 2001-07-16 Pharmaceutical composition improved in peroral absorbability

Country Status (10)

Country Link
US (2) US7008640B2 (en)
EP (1) EP1302201A4 (en)
JP (2) JP3563070B2 (en)
KR (1) KR100863146B1 (en)
CN (1) CN1224423C (en)
AU (2) AU7105501A (en)
CA (1) CA2415643C (en)
HU (1) HUP0303700A3 (en)
MX (1) MXPA03000520A (en)
WO (1) WO2002005786A1 (en)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL371264A1 (en) * 2001-12-21 2005-06-13 The Procter & Gamble Company Method for the treatment of bone disorders
KR100937113B1 (en) * 2002-01-16 2010-01-18 아스텔라스세이야쿠 가부시키가이샤 Medicinal compositions for improving oral absorption
NZ535705A (en) * 2002-05-10 2007-08-31 Hoffmann La Roche Ibandronic acid for the treatment and prevention of osteoporosis
FR2841138B1 (en) * 2002-06-25 2005-02-25 Cll Pharma SOLID PHARMACEUTICAL COMPOSITION COMPRISING A LIPOPHILIC ACTIVE INGREDIENT, ITS PREPARATION PROCESS
US20060003004A1 (en) * 2002-10-25 2006-01-05 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
US20060024366A1 (en) * 2002-10-25 2006-02-02 Collegium Pharmaceutical, Inc. Modified release compositions of milnacipran
US20040121010A1 (en) * 2002-10-25 2004-06-24 Collegium Pharmaceutical, Inc. Pulsatile release compositions of milnacipran
DK1790347T3 (en) * 2002-12-20 2015-01-19 Hoffmann La Roche Ibandronate high-dose-formulation
TWI355276B (en) * 2003-01-14 2012-01-01 Akira Tsuji Gastrointestinal absorption enhancer mediated by p
FR2850577B1 (en) * 2003-02-03 2005-04-15 Ethypharm Sa MASK TASTE ENRICHED PARTICLES, PROCESS FOR THEIR PREPARATION AND ORODISPERSIBLE COMPRESSES CONTAINING SAID PARTICLES
ZA200409537B (en) * 2003-01-31 2006-10-25 Yamanouchi Pharma Co Ltd Stable solid medicinal composition for oral administration
US7442387B2 (en) * 2003-03-06 2008-10-28 Astellas Pharma Inc. Pharmaceutical composition for controlled release of active substances and manufacturing method thereof
TR200300510A2 (en) * 2003-04-18 2004-11-22 Sanovel �La� Sanay� Ve T�Caret A.�. Dispersing alendronate microparticle formulation
US7358270B2 (en) * 2004-01-30 2008-04-15 Astellas Pharma Inc. Treating agent for irritable bowel syndrome
US20050182028A1 (en) * 2004-02-13 2005-08-18 Chen Chih-Ming J. Pharmaceutical formulation for oral delivery of bisphosphates
ATE475412T1 (en) * 2004-05-24 2010-08-15 Warner Chilcott Co Llc ENTERIC SOLID ORAL DOSAGE FORM OF A BISPHOSPHONATE WITH A CHELATE
ES2644450T3 (en) 2004-12-31 2017-11-29 Dr. Reddy's Laboratories Ltd. New benzylamine derivatives as CETP inhibitors
US8604055B2 (en) 2004-12-31 2013-12-10 Dr. Reddy's Laboratories Ltd. Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors
JP4632204B2 (en) * 2005-09-21 2011-02-16 アステラス製薬株式会社 Antidiarrheal irritable bowel syndrome treatment
AU2007208214B2 (en) * 2006-01-24 2013-02-14 Paratek Pharmaceuticals, Inc. Methods of increasing oral bioavailability of tetracyclines
PL2007362T3 (en) 2006-04-04 2019-02-28 Kg Acquisition Llc Oral dosage forms including an antiplatelet agent and an acid inhibitor
US20090074872A1 (en) * 2006-06-26 2009-03-19 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
US20080050450A1 (en) * 2006-06-26 2008-02-28 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
WO2008012830A1 (en) * 2006-07-28 2008-01-31 Hetero Drugs Limited Soup faropenem free acid
ES2496166T3 (en) * 2006-12-22 2014-09-18 Yuhan Corporation Solid dispersion containing revaprazan and its preparation process
WO2008081829A1 (en) 2006-12-27 2008-07-10 Astellas Pharma Inc. Aminoalkylmethacrylate copolymer e for maintaining solubility of poorly water-soluble drug
US7605148B2 (en) * 2007-04-16 2009-10-20 Aurobindo Pharma Ltd. Aqueous oral solution of bisphosphonic acid
EP2155166A2 (en) * 2007-05-11 2010-02-24 F. Hoffmann-Roche AG Pharmaceutical compositions for poorly soluble drugs
KR101007865B1 (en) * 2007-06-18 2011-01-14 연세대학교 산학협력단 Sustained-release chitosan capsules comprising chitosan and phytic acid
DE102007060175A1 (en) 2007-12-13 2009-06-18 Johannes Gutenberg-Universität Mainz Quaternization of the additive aminoalkyl methacrylate copolymer E to improve the permeability and solubility of drugs
US20090226515A1 (en) * 2008-03-04 2009-09-10 Pharma Pass Ii Llc Statin compositions
CN101548978B (en) * 2008-04-03 2012-11-21 万特制药(海南)有限公司 Pharmaceutical composition containing alendronate sodium
US20100159010A1 (en) * 2008-12-24 2010-06-24 Mutual Pharmaceutical Company, Inc. Active Agent Formulations, Methods of Making, and Methods of Use
CN105419206B (en) * 2009-07-30 2017-12-15 赢创罗姆有限公司 Powdered or granular composition comprising copolymer, dicarboxylic acids and aliphatic mono-carboxylic acids
KR101647869B1 (en) 2009-07-30 2016-08-11 에보니크 룀 게엠베하 Powdery or granulated composition comprising a copolymer, a dicarboxylic acid and a fatty monocarboxylic acid
US9169279B2 (en) 2009-07-31 2015-10-27 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
US20160016982A1 (en) 2009-07-31 2016-01-21 Thar Pharmaceuticals, Inc. Crystallization method and bioavailability
LT2459176T (en) * 2009-07-31 2017-12-11 Grünenthal GmbH Crystallization method and bioavailability
FR2954320B1 (en) 2009-12-17 2012-06-15 Cll Pharma SUPPLEMENTALLY AVAILABLE ORAL PHARMACEUTICAL COMPOSITION CONTAINING BIPHOSPHONIC ACID OR ONE OF ITS SALTS
HUE026713T2 (en) 2010-02-25 2016-07-28 Evonik Roehm Gmbh Pharmaceutical or nutraceutical formulation
ES2688278T3 (en) 2010-05-10 2018-10-31 Evonik Röhm Gmbh Pharmaceutical dosage form comprising one or more active antiretroviral ingredients
EP2592080B1 (en) 2010-06-23 2016-02-24 Astellas Pharma Inc. Crystal of fused pyridine compound salt
CN102309442A (en) * 2010-07-07 2012-01-11 澳美制药厂 Ambroxol hydrochloride oral aqueous composition and preparation method thereof
US9011912B2 (en) 2010-10-07 2015-04-21 Abon Pharmaceuticals, Llc Extended-release oral dosage forms for poorly soluble amine drugs
WO2012071517A2 (en) 2010-11-24 2012-05-31 Thar Pharmaceuticals, Inc. Novel crystalline forms
RU2013139701A (en) 2011-02-17 2015-03-27 Ф. Хоффманн-Ля Рош Аг METHOD FOR CONTROLLED CRYSTALLIZATION OF AN ACTIVE PHARMACEUTICAL INGREDIENT FROM THE STATE OF A COOLED LIQUID BY EXTRUSION OF HOT DECAY
CN102144982B (en) * 2011-03-30 2012-12-12 江苏神龙药业有限公司 Minodronate tablets and preparation method thereof
FR2975300B1 (en) * 2011-05-19 2013-06-07 Thierry Breul PHARMACEUTICAL COMPOSITION WITH IMPROVED BIOAVAILABILITY
CN102949358B (en) * 2011-08-17 2015-10-21 山东新时代药业有限公司 A kind of minodronic acid tablet and preparation method thereof
US9199967B2 (en) 2011-08-18 2015-12-01 Dr. Reddy's Laboratories Ltd. Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors
CN103958511A (en) 2011-09-27 2014-07-30 雷迪博士实验室有限公司 5 - benzylaminomethyl - 6 - aminopyrazolo [3, 4 -b] pyridine derivatives as cholesteryl ester -transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis
US20140128431A1 (en) 2012-04-03 2014-05-08 Hoffmann-Laroche Inc. Pharmaceutical composition with improved bioavailability, safety and tolerability
EP2649989B1 (en) 2012-04-13 2017-10-18 King Saud University Method for preparing a solid dispersion, solid dispersion obtained thereby and use thereof
US20170071930A1 (en) 2012-11-19 2017-03-16 Dr. Reddy's Laboratories Ltd. Pharmaceutical compositions of cetp inhibitors
MY192032A (en) 2013-01-22 2022-07-24 Hoffmann La Roche Pharmaceutical composition with improved bioavailability
JP6910950B2 (en) * 2015-01-12 2021-07-28 エンテリス・バイオファーマ・インコーポレイテッドＥｎｔｅｒｉｓ Ｂｉｏｐｈａｒｍａ，Ｉｎｃ． Solid oral dosage form
WO2017208070A1 (en) 2016-05-31 2017-12-07 Grünenthal GmbH Bisphosphonic acid and coformers with lysin, glycin, nicotinamide for treating psoriatic arthritis

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4786508A (en) 1986-05-30 1988-11-22 Warner-Lambert Company Coated dosage forms
JPH0215027A (en) 1988-07-01 1990-01-18 Takada Seiyaku Kk Novel probucol solid preparation
JP2879344B2 (en) * 1989-04-07 1999-04-05 富山化学工業株式会社 Anti-inflammatory preparation containing 3-formylamino-7-methylsulfonylamino-6-phenoxy-4H-1-benzopyran-4-one or a salt thereof
US5445830A (en) * 1989-07-25 1995-08-29 Otsuka Pharmaceutical Co., Ltd. Highly absorbable pharmaceutical composition
JPH0374396A (en) * 1989-08-16 1991-03-28 Mercian Corp Antimicrobial composition
US5102668A (en) * 1990-10-05 1992-04-07 Kingaform Technology, Inc. Sustained release pharmaceutical preparation using diffusion barriers whose permeabilities change in response to changing pH
JP2893140B2 (en) * 1990-11-30 1999-05-17 エスエス製薬株式会社 Stable vitamin D preparation
CA2108575C (en) 1991-04-16 2002-10-22 Kouichi Nakamichi Method of manufacturing solid dispersion
JP3454517B2 (en) * 1991-04-25 2003-10-06 京都薬品工業株式会社 Oral flavoring
JP2973751B2 (en) * 1991-12-04 1999-11-08 大正製薬株式会社 Method for producing flavored oral composition
JP3265680B2 (en) 1992-03-12 2002-03-11 大正製薬株式会社 Oral pharmaceutical composition
JPH0674396A (en) 1992-08-26 1994-03-15 Nippon Sanso Kk Gas filling method
US5431920A (en) * 1993-09-21 1995-07-11 Merck Frosst, Canada, Inc. Enteric coated oral compositions containing bisphosphonic acid antihypercalcemic agents
US5462932A (en) * 1994-05-17 1995-10-31 Merck & Co., Inc. Oral liquid alendronate formulations
KR100404293B1 (en) * 1995-05-02 2004-02-18 다이쇼 세이야꾸 가부시끼가이샤 Composition for Oral Administration
DE19615812A1 (en) 1996-04-20 1997-10-23 Boehringer Mannheim Gmbh Pharmaceutical preparation containing diphosphonic acids for oral administration
EP1027036A2 (en) * 1997-10-03 2000-08-16 ELAN CORPORATION, Plc Taste masked formulations
DE19814256A1 (en) * 1998-03-31 1999-10-07 Asta Medica Ag Solid, fast-breaking cetirizine formulations
MXPA01000032A (en) * 1998-07-08 2002-10-17 Kirin Amgen Inc Powdery preparation for mucosal administration containing polymeric medicine.
GT199900148A (en) * 1998-09-10 2001-02-28 Denaturing for the sympathomimetic amine salts.
JP4599714B2 (en) * 1999-01-22 2010-12-15 アステラス製薬株式会社 Oral absorption improving pharmaceutical composition
EP1273306A4 (en) * 2000-03-31 2005-06-22 Kirin Brewery Powdery preparation for transmucosal administration containing a polymeric form of drug and exhibiting improved storage stability

Similar Documents

Publication Publication Date Title
AU2001271055A1 (en) Pharmaceutical composition improved in peroral absorbability
AU7105501A (en) Pharmaceutical composition improved in peroral absorbability
AU2002222567A1 (en) Composition improved in solubility or oral absorbability
AU781269C (en) Pharmaceutical compositions
IL152659A0 (en) Pharmaceutical composition
HK1075889A1 (en) Pharmaceutical composition
EG24357A (en) New Pharmaceutical composition
AU2001250420A1 (en) Pharmaceutical compositions
AU2001237525A1 (en) Azetidine derivatives, preparation thereof and pharmaceutical compositions containing same
HUP0204555A3 (en) Pharmaceutical composition
AU2001274307A1 (en) Pharmaceutical compositions
HUP0301042A3 (en) Pharmaceutical composition useful in contraception
AU7645701A (en) Cosmetic or pharmaceutical composition in solid form comprising bis-acyl-amides
AU2002221115A1 (en) Medicinal compositions having improved absorbability
AU2001290239A1 (en) Medicinal composition
IL154238A0 (en) Pharmaceutical composition
AU2001273919A1 (en) Pharmaceutical compositions
AU2001232017A1 (en) Pharmaceutical composition for pulmonary delivery
AU4085201A (en) Pharmaceutical composition
AU2001278705A1 (en) Pharmaceutical composition
AU3586401A (en) Pharmaceutical composition
AU2001274587A1 (en) Polymer-containing drug composition
AU2001285737A1 (en) Pharmaceutical compositions
GB0015361D0 (en) Improvements in pharmaceutical compositions
AUPQ678400A0 (en) Pharmaceutical composition